España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sanofi aventis s.a. - ramipril - comprimido - 2,5 mg - ramipril 2,5 mg - ramipril

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

casen recordati s.l. - nitroglicerina - parche transdÉrmico - 15 mg/24 h - nitroglicerina 15 mg/24 h - trinitrato de glicerilo

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratoire hra pharma - levonorgestrel - excipientes: lactosa hidratada,almidon de maiz - anticonceptivos hormonales para uso sistÉmico - anticonceptivos de emergencia - levonorgestrel

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios alter s.a. - pregabalina - cÁpsula dura - 100 mg - pregabalina 100 mg - pregabalina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios alter s.a. - pregabalina - cÁpsula dura - 200 mg - pregabalina 200 mg - pregabalina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fresenius kabi ab - serina, glucosa anhidra, potasio cloruro, aceite soja purificado, fenilalanina, triptofano, glicerofosfato sodio, glicerina, glutamico acido, histidina, isoleucina, leucina, treonina, metionina, calcio cloruro, magnesio sulfato, prolina, acetato sodio, lisina, valina, alanina, tirosina, arginina, aspartico acido - emulsiÓn para perfusiÓn - n/a (más de 4 pa) - n/a (más de 4 pa) n/a (más de 4 pa) - combinaciones

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

astrazeneca farmaceutica spain s.a. - budesonida; formoterol fumarato dihidrato - polvo para inhalaciÓn - 320 microgramos/9 microgramos/dosis - budesonida 320 microgramos; formoterol fumarato dihidrato 9 microgramos - formoterol y budesonida

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. excepto en recién diagnosticados de lmc en fase crónica, no existen ensayos controlados que demuestran un beneficio clínico o el aumento de la supervivencia para estas enfermedades. .

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vetpharma animal health s.l. - doxiciclina hiclato - polvo para administraciÓn en agua de bebida - doxiciclina hiclato 580 - doxiciclina - cerdos de engorde; pollos reproductores; pollos de engorde; pavos reproductores; pavos de engorde

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

teva pharma s.l.u. - esomeprazol magnesico - cÁpsula dura gastrorresistente - 40 mg - esomeprazol magnesico 40 mg - esomeprazol